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ABSTRACT 
 
Objectives Mast cells (MCs) are involved in the pathogenesis of rheumatoid arthritis (RA). 
However, their contribution remains controversial. To establish their role in RA, we analysed 
their presence in the synovium of treatment-naïve early RA patients and their association and 
functional relationship with histological features of synovitis. 
Methods Synov al tissue was obtained by ultrasound-guided biopsy from treatment-naïve 
patients with early RA (n=99). Immune cells (CD3/CD20/CD138/CD68) and their 
relationship with CD117+ MCs in synovial tissue were analysed by immunohistochemistry 
(IHC) and immunofluorescence (IF). The functional involvement of MCs in ectopic 
lymphoid structures (ELS) was investigated in vitro, by co-culturing MCs with naïve B cells 
and anti-citrullinated protein antibodies (ACPA)-producing B cell clones, and in vivo in 
interleukin-27 receptor (IL27ra)-deficient and control mice during antigen-induced arthritis 
(AIA). 
Results High synovial MC counts are associated with local and systemic inflammation, 
autoantibody positivity, and high disease activity. IHC/IF showed that MCs reside at the 
outer border of lymphoid aggregates. Furthermore, human MCs promote the activation and 
differentiation of naïve B cells, and induce the production of ACPA, mainly via contact-
dependent interactions. In AIA, synovial MC numbers increase in IL27ra deficient mice, in 
association with ELS and worse disease activity. 
Conclusions Synovial MCs identify early RA patients with a severe clinical form of 
synovitis characterised by the presence of ELS. 
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INTRODUCTION 
 
Mast cells (MCs) are tissue-resident cells of the innate immunity, involved in several 
physiological and pathological processes, including infections, cancer and chronic 
inflammatory diseases[1,2]. They are present in the synovial membrane (SM) and have been 
implicated in contributing to the inflammatory response in several rheumatic diseases[3], 
including rheumatoid arthritis (RA)[4]. Notably, MCs are present in healthy synovia[5], but 
their number significantly increases accompanying the cellular hyperplasia characteristic of 
RA synovitis[6–8]. Many MC mediators have direct pro-arthritogenic effects[9–12], and 
MCs can be activated by several stimuli present in the synovium/synovial fluid, such as anti-
citrullinated protein antibodies (ACPA) IgG immune complexes[13]. On the other hand, 
recent evidences suggest that MC contribution to autoimmune diseases can be complex and 
multifaceted[14]. In the context of RA, for example, human MCs have been shown to exert 
immunomodulatory functions in vitro[15]. In vivo, initial findings were contrasting[16–18], 
most likely because of the use of animal models in which MC depletion was accompanied by 
anomalies of other immune cells[19]. In recent years, thanks to the development of new 
specific models of MC-depletion[20], their contribution has been confirmed to be essential in 
collagen-induced arthritis (CIA) but redundant in serum-transfer arthritis[21]. Additionally, 
their depletion in the pre-clinical phases of CIA, rather than in the established phases, was 
shown to influence the disease outcome[22]. These evidences in vivo suggest that MC 
contribution to RA may be different in various disease stages, i.e. essential during the early 
phases (assessed by CIA), but somehow dispensable during the late effector phases (serum 
transfer). However, while these models are self-resolving, in RA there is chronic 
inflammation with a perpetuation of the aberrant autoimmune response; therefore, the results 
cannot be easily translated to the clinical setting. Overall, despite the substantial amount of 
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data, the role of MCs in RA remains to be clarified [4]. As RA is well-recognized as an 
heterogeneous syndrome in terms of genetic predisposition, pathogenesis, clinical[23,24], and 
histological[25] features, it could be hypothesised that MC presence and functions in the 
synovium may be different in various disease subsets. To explore this hypothesis, we 
systematically analysed the presence of MCs in the synovia of a large cohort of disease-
modifying anti-rheumatic drugs (DMARD)-naïve early RA patients. Furthermore, we 
assessed their interactions with immune cells at synovial level and analysed in vitro the 
crosstalk of MCs with B cells. Finally, we evaluated the relationship between MC synovial 
infiltration and ectopic lymphoid structures (ELS) in an experimental model of synovial 
ectopic lymphoid neogenesis. 
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Methods 
 
Patient samples and ultrasound-guided synovial biopsy  
 
Synovial tissue was obtained by ultrasound-guided synovial biopsy from DMARD-naïve 
patients with early (<12 months) RA (n=99), enrolled in the Pathobiology of Early Arthritis 
Cohort (PEAC) cohort of the Centre for Experimental Medicine and Rheumatology of Queen 
Mary University (London), as previously described[26]. All patients fulfilled the 2010 
EULAR criteria for RA[27]. All procedures were performed following written informed 
consent and were approved by the hospital’s ethics committee (REC 05/Q0703/198). 
 
Histological analyses of synovial samples 
Synovial sections underwent standard H&E staining and semi-quantitative (SQ) assessment 
of synovitis according to a previously validated score (Krenn) [28]. Sequentially cut sections 
underwent Immunohistochemical (IHC) staining and SQ assessment (0-4) for immune cells, 
as previously reported[29] and automated image analysis and counting for CD117+ve MCs. 
Patients were classified into high, intermediate and low MC groups (>66th, 33rd-66th, <33rd 
percentiles, respectively). Supplementary methods. 
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Peripheral blood-derived MCs 
CD34+ hematopoietic stem cells (StemPro® CD34+ kit, ThermoFisher) were differentiated 
into MCs as previously described[30]. Supplementary methods and Supplementary Figure 1 
for MC purity. 
 
Naïve B cell isolation and co-culture with MCs 
IgD+ B cells isolated by immunomagnetic sorting (Miltenyi) from tonsil mononuclear cells 
were cultured for 7 days alone or together with MCs, in the presence of TLR-9 ligand (CpG 
ODN-2006, Invitrogen), in contact or separated by a Transwell© membrane. In parallel 
experiments, B cells were marked with CFSE (Biolegend) to measure proliferation. Where 
indicated, mouse anti-human CD154 (CD40L) or isotype control (Biolegend) were added at a 
concentration of 0.1-10 !g/mL. Supplementary methods. 
 
Visualization of MC-B cell interaction  
Supplementary methods. 
 
ACPA B cell clone and co-culture with MCs 
ACPA-producing immortalized B-cells (2 x 105) were obtained as described (Germar, K et al. 
Manuscript submitted and[31]) and cultured as indicated in supplementary methods.  
 
 
Flow cytometry 
Flow cytometry staining was performed as previously described[32]. Supplemetary methods  
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Measurement of immunoglobulins 
IgG and IgM were measured using the IgG and IgM ELISA Kits (Bethyl), according to the 
manufacturer instructions. For the measurement of ACPA, anti-CCP2-IgG was measured by 
ELISA (Immunoscan-RA Mark 2; Eurodiagnostica). 
 
Antigen induced arthritis(AIA) in wild-type and IL27ra KO 
AIA was induced in adult (8–12 wk) IL27ra-/- mice and age/sex-matched WT as previously 
described [33]. 5 !m sections of synovia from animals culled at different intervals (days 3, 10 
and 35) were processed and analysed as described [33]. To visualize MCs, sequentially-cut 
sections were stained with acidic Toluidine Blue (Sigma) 0.1% solution (pH 2.0~2.5). 
Supplementary methods. 
 
Statistical analyses 
Measures of central tendency and dispersions and statistical analyses are indicated in each 
figure legend and in supplementary methods. P values of <0.05 were considered statistically 
significant.
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RESULTS 
 
Mast cells strongly associate with defined histological features of synovitis and markers 
of disease activity in patients with early RA 
To evaluate the association of MCs with different clinical and histological phenotypes of RA 
in an unbiased setting, we studied their presence in the synovial membranes of patients with 
early RA, naïve to treatment with DMARDs. Table 1 summarises the demograhic feaures of 
the patient cohort, which are as expected for a population with early untreated RA i.e. active 
disease - mean disease activity score (DAS)-28 5.62, high inflammatory markers - mean ESR 
38 mm/h, and approximately 70% auto-antibody positive – rheumatoid factor (RF) or ACPA. 
  
Page 10 of 75
https://mc.manuscriptcentral.com/ard
Annals of the Rheumatic Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review
 O
nly
10 
 
Table 1. Summary of patient characteristics (n=99) 
Age, years mean (SD), range 52 (16) 19-89 
Sex (% Female) 70.7% 
 
Disease duration (Months) mean (SD), 
range 6 (3) 1-12 
ACPA+ % 75.8% 
 
RF+ % 73.7% 
 
ESR mm/h mean (SD), range 38 (30) 2-120 
CRP mg/L mean (SD), range 17 (25) 0-162 
DAS-28 mean (SD), range 5.62 (1.41) 1.88-8.92 
TJC mean (SD), range 11.33 (7.14) 1-28 
SJC mean (SD), range 7.33 (5.88) 1-26 
VAS (PGA) mean (SD), range 66.25 (24.57) 0-100 
HAQ mean (SD), range 1.51 (0.79) 0-4.2 
 
ACPA: anti-citrullinated protein antibodies; RF: rheumatoid factor: ESR: erythrocyte sedimentation rate; CRP: C reactive protein; DAS-28: 
disease activity score 28 joints; TJC: tender joint count; SJC: swollen joint count; VAS visual analogic scale; PGA Patient Global disease 
Activity; HAQ: health assessment questionnaire.  
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First, we assessed the correlation of MC density with markers of both local (i.e. synovial) and 
systemic inflammation and disease activity. Figure 1A demonstrates that MC counts 
significantly correlate with inflammatory markers - erythrocyte sedimentation reate (ESR) 
and c-reactive protein (CRP), disease activity (DAS-28), and synovial inflammation (Krenn 
Score). Interestingly, MCs correlated with other immune cells in synovial membranes, with 
particularly high correlation indexes for B cell) and T cells scores (Spearman r 0.617 and 
0.519, respectively, p<0.001). Since MC infiltration in synovial specimens was heterogenous, 
we stratified patients according to the number of MCs into three groups (low, medium and 
high MC counts), as shown in figure 1B. Consistent with the strong correlation shown in 
figure 1A, high T and B cell scores were predominant in patients with high MC counts 
(figure 1C-D). As these data indicate that MCs correlate with synovial inflammation and the 
degree of lymphocyte infiltration, we evaluated the presence of MCs in three classified forms 
of synovitis (pathotypes): Lymphoid, Myeloid and Pauci-immune/Fibroid [25]. Interestingly, 
more than 80% of patients with high MC synovial counts displayed a lymphoid-rich 
pathotype, characterised by synovial T- and B-cell aggregates; viceversa, as expected, the 
number of MCs was significantly higher in patients with a lymphoid pathotype (figure 1E and 
1F). These data indicate that MCs are strongly associated with lymphoid aggregates in the 
synovia of patients with early RA. Next, we investigated the heterogeneity of synovial MCs. 
Two types of MCs have been described in humans, expressing tryptase alone (MC_T) or 
tryptase and chymase (MC_TC), with the following distribution in synovium: predominance 
of MC_TC in normal synovium[5], expansion of both in RA[7], with relative incresase of 
MC_T described in early [8] and late RA [34]. By performing double immunofluorescence in 
a subgroup of patients from our early RA cohort (n=15), we found both types of MCs 
expressed in the synovia, with significantly higher levels of MC_TC  (Supplementary Figure 
S2A), and an average ratio MC_TC:MC_T of 1:3.  When patients were stratified according to 
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pathotypes, we observed a significant increase of both types of MCs in the lymphoid 
pathotype (Supplementary Figure S2B), with the ratio MC_TC:MT_C changing from 1:6 
(fibroid) to 1:2 (lymphoid). Additionally, MC_T, and not MC_TC, showed a significant 
correlation with synovial inflammation (Supplementary Figure S2C-D). Supplementary 
Figure S2E shows a representative image with a predominance  of MC_T in a patient with 
lymphoid pathotype. These data suggest an enrichment of tryptase expressing synovial MCs 
(MC_T) in the lymphoid pathotype in association with the degree of inflammation. 
Finally, we assessed the clinical phenotype of patients stratified according to MCs. As shown 
in table 2, patients with medium and high MC counts have significantly raised ESR and 
disease activity (DAS28) compared to low MC counts, and patients with high MCs have a 
significantly higher prevalence of auto-antibody positivity (ACPA and RF) compared to low 
and medium MCs.. To exclude that the association of MCs with disease severity was 
exclusively driven by their association with lymphoid cells, we performed additional analyses 
excluding lymphoid patients, and found that MCs were significantly correlated with ESR 
(Spearman r=0.272 p=0.007), CRP (r=0.217 p=0.033), and DAS-28 (r=0.308 p=0.002). 
Overall, this suggests that the stratification of patients according to synovial MCs identifies 
patients with a severe clinical phenotype. 
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Table 2.  Clinical phenotype of patients stratified according to MC numbers.  
  MAST CELLS  
 
All 
(n=99, 
100%) 
Low 
(n=32) 
Medium 
(n=33) 
High 
(n=34) 
All 
(n=99, 
100%) 
Age mean (SD)) 52 (16) 50 (15) 54 (17) 52 (15) 0.300 
Female % 70.7% 68.8% 71.9% 72.7% 0.704 
ESR mean (SD) 38 (30) 27 (28) 42 (30) 45 (30) 0.033 
CRP mean (SD) 17 (25) 10 (29) 21 (23) 18 (24) 0.174 
RF+ % 73.7% 68.8% 60.6% 91.2% 0.031 
ACPA+ % 75.8% 78.1% 60.6% 88.2% 0.009 
DAS28 mean (SD) 5.65(1.41) 4.97 (1.54) 6.05 (1.22) 5.91 (1.24) 0.003 
Fisher’s exact test or ANOVA, as appropriate  
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Mast cells interact with T and B cells in follicular structures in RA synovium and tonsil 
tissue 
Having established the presence of MCs in the synovial biopsies from early RA patients with  
lymphoid-rich sysnovitis, we next investigated the distribution of MCs in the synovia of 
patients with a lymphoid pathotype. A representative example of the synovial histology of 
these patie ts is shown in Figure 2A.  Immunohistochemical staining of sequential sections 
confirmed the presence of CD117+ synovial MCs (figure 2B). By immunofluorescence, we 
identified MCs bordering lymphoid aggregates, in close contact with B and T cells (figure 
2C). A similar distributon was observed in the highly organised secondary lymphoid organs 
(SLO) from tonsil tissue, used as controls (figure 2D).  
Thus, MCs reside on the outer boundary of B and T cell aggregates, and are a histological 
feature of both synovial ELS, and SLOs.  
 
Mast cells enhance B cells survival, proliferation and differentiation and production of 
class-switched Ig and ACPA via CD40L 
As MCs were found in the proximity of B and T cell aggregates in synovial membranes, and 
because the activation of B cells toward the production of autoantibodies locally contributes 
to the pathogenic process in RA[29], we hypothesised that human MCs could influence the 
activation of B cells. To test this hypothesis, we cultured naïve B cells isolated from tonsils 
with in vitro differentiated human MCs, using the TLR9 ligand CpG to boost B cell 
activation[35]. MCs enhanced the survival of naïve B cells (figure 3A) with a significant 
increase in IgG secretion but only minor changes in IgM production (figure 3B). Since CpG 
per se lacks the ability to induce a full differentiation of naïve B cells[36,37], the production 
of IgG upon co-culture of MCs with naïve B cells suggest that MCs can provide additional 
signals allowing B cell differentation and the isotype switch toward IgG (figure 3B). 
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Interestingly, cell contact was not necessary to induce the MC-mediated effect on B cell 
survival, indicating that soluble factors were sufficient (figure 3C). Additionally, MCs were 
enhancing the proliferation of CFSE-labelled naïve B cells,  and this effect was again not 
dependent on cell contact (figure 3D). On the contrary, the production of IgG was 
significantly dependent on cell contact, suggesting that membrane-bound factors were 
responsible (figure 3E). Similarly, MCs were able to ehnahce the production of RA specific 
autoantibodies (ACPA) by B cells (figure 3F), an effect again dependent on cell contact. 
Collectively, these data indicate that MCs can induce the survival, proliferation and 
differentiation of naïve B cells toward IgG-secreting B cells via indirect and direct cell-cell 
contact.  
Next, we investigated the mechanisms by which MCs promote IgG production by B cells and 
demonstrated that this is CD40L-dependent (figure 3G), confirming previous reports 
indicating that murine MCs mediate B cell activation through this cell surface costimulatory 
molecule[38,39].  
To further confirm the ability of MCs to induce the differentiation of naïve B cells toward 
antibody-producing memory B cells, we analysed B cells by flow cytometry after 7 days of 
co-culture with MCs. Figure 3H shows that co-culture of naïve B cell with MCs increased the 
number of antibody-producing memory B cells (CD27+CD38+). Interestingly, this effect 
could be inhibited by treatment with anti-CD40L in a dose-dependent manner, further 
confirming the ability of MCs to induce of B cell differentiation via CD40L-CD40 interaction 
(figure 3H). 
As cell contact was crucial for the MC-induced differentiation of B cells, we performed 
phalloidin staining on MCs and B cells after 24h of co-culture, which showed actin re-
organisation in the region of contact between MCs and B cells (figure 3I). This suggests an 
active cellular interaction between MCs and B cells. 
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Synovial mast cell infiltration occurs early and is associated with ELS and disease 
severity in antigen-induced arthritis in IL27ra deficient mice  
Having demonstrated that human MCs enhance B cell activation and differentiation in vitro 
and are associated with synovial ELS in patients with early RA, we wished to investigate in 
vivo the relevance of the interaction between MCs and B cells within ELS in the pathogenesis 
of arthritis. To this end, we examined MCs synovial infiltration in AIA, a model in which 
acute inflammatory arthritis is induced by intra-articular injection of methylated bovine 
serum albumin (mBSA) following systemic immunization with the same antigen. We utilised 
IL27ra-deficient mice, which develop exacerbated synovitis comprising ELS[33]. 
Figure 4A and B show that MCs were present already in the early phases of AIA (three days 
after intra-articular injection), with their numbers further increasing at day 10 (d10) and day 
35 (d35) post-arthritis induction. Importantly, in IL27ra-deficient mice, synovial MC 
infiltration was significantly higher compared to wild-type littermates at d10 and d35 (figure 
4C-D). Moreover, at the peak of inflammation (day 10) synovial MCs showed a positive 
correlation with arthritis index, synovial infiltrate and the presence of erosions (figure 4E). 
Finally, in IL27ra deficient animals at day 10, there was a trend towards a correlation 
between MCs and the area of lymphoid aggregates (figure 4F) and MCs were found at the 
borders of lymphoid aggregates (figure 4G), reflecting the observations in RA patients with a 
lymphoid pathotype.  
Overall, these observations confirm the association of MCs with ectopic lymphoid neogenesis 
and disease severity, during arthritis induction in vivo.  
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Discussion 
In this manuscript, we present the first systematic analysis of MCs in the synovial membrane 
(SM) of early RA patients obtained by US-guided synovial biopsy prior to therapeutic 
intervention. Our data demonstrate that synovial MCs are strongly associated with specific 
pathobiological and clinical phenotypes potentially linked to their ability to induce the 
activation/differentiation of B cells and the production of ACPA autoantibodies.  
Although MCs have long known to be part of the inflammatory infiltrate in RA, their 
presence in the SM has only been analysed in a few studies, which described increased MC 
numbers and mediators in the SM and synovial fluid of RA patients, possibly in correlation 
with disease activity[6–8]. More recently, in a study describing the immunopathologic 
characteristics of ultrasound-defined synovitis in RA patients in remission, the presence of 
synovial MCs and B cells at baseline was associated with disease reactivation at follow-
up[40]. At the same time, studies in vitro and in vivo have yielded contradictory results, so 
that their exact contribution is still unclear[4].   
To obtain further insight into the relevance of MCs in RA, we analysed the SM of a large 
cohort of patients with early (<12 months) RA (n=99), unbiased by treatment and disease 
duration. 
Our data demonstrate high synovial MC counts in patients with a severe clinical phenotype at 
baseline. Furthermore, MCs correlate with synovial inflammation and, in particular, with 
ectopic lymphoid structures (ELS), which are found in approximately 40% of RA patients 
and have been associated with disease severity, T cell priming and autoantibody production, 
including the local on-going production of class-switched autoantibodies, such as 
ACPA[29,41]. Interestingly, we found a higher prevalence of tryptase-expressing MCs 
(MC_T) in the synovia of patients with ELS. Although the concept of MC heterogeneity is 
Page 18 of 75
https://mc.manuscriptcentral.com/ard
Annals of the Rheumatic Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review
 O
nly
18 
 
still ill-defined[42], the prevelence of MC_T in association with the lymphoid pathotype 
would be in line with the pro-inflammatory role of this subpopulation described in 
asthma[43]. The strong association of MCs with ELS led us to hypothesise that MCs could 
modulate the local adaptive immune response. The ability of human MCs to influence T cells 
interaction has already been shown[44,45]. Murine MCs  have been shown to activate B cells 
and promote their differentiation toward effector cells[38,46]. Interestingly, murine MCs 
were also shown to control, via CD40/CD40L interaction, the expansion and differntiation of 
IL-10-competent B cells, which is in line with their immunomodulatory functions[39]. The 
interaction of human MCs and B cells has been poorly studied: in the context of allergic 
responses, MCs have been shown to express CD40L and induce IgE production by B 
cells[47,48], while  in the context of cancer they have been shown to activate 
lymphoplasmacytic cells via CD40L[49]. Nonetheless, the interaction between human MCs 
and B cells has never been studied in the context of autoimmune diseases characterised by 
local B cell responses.  
Here, we show that MCs are at the border of B and T cell aggregates in the synovia of RA 
patients, similarly to the distribution observed in secondary lymphoid organs. Furthermore, 
we show that human MCs support the survival, activation, proliferation and differentiation of 
naive B cells into IgG-producing B cells, in line with recent results in mice [46]. This effect 
is dependent on cell contact and, specifically, on CD40L-CD40 interaction. Importantly, we 
demonstrate that MCs induce ACPA production by B cells, also in a contact-dependent 
manner. Furthermore, we provide the first evidence of an active interaction between human 
MCs and B cells, as previously shown for MC-T cells[50] and MC-DCs[51]. In vivo, we used 
antigen-induced arthritis (AIA) to assess the timecourse and magnitude of synovial MC 
infiltration, and IL27ra deficient mice as a model of exacerbated synovitis accompanied by 
ELS formation[33], thus resembling RA patients with a lymphoid pathotype. In both wild-
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type and IL27ra deficient animals, we observed an early synovial MC infiltration, before the 
formation of ELS, further increasing at later stages. Whether the early synovial infiltration of 
MCs means that they are essential to lymphoid neogenesis remains to be established. In fact, 
in addition to the direct modulation of lymphocyte  activation, MCs are also known to 
produce several mediators[52], including angiogenic and lymphangiogenic factors[53][54], 
that could support the organization of ELS [55].  Interestingly, MC numbers were 
significantly higher in IL27ra deficient animals, in association with synovial ELS and a 
worse disease outcome. As IL27ra deficiency has been shown to enhance the activation of 
MCs in the context of Th2 responses [56,57], it will be of interest to further assess the 
specific role of IL27-mediated MC inhibition in autoimmune diseases.  
In conclusion, our study points to the relevance of MCs in RA and their role as novel markers 
of synovial inflammation. In fact, their presence contributes to the definition of a MC-rich 
highly inflamed synovial pathotype and helps identifying patients with a severe clinical 
phenotype.  
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Data sharing statement: n.a. FIGURE LEGENDS 
 
Figure 1 Association of high mast cell counts with synovial inflammation, disease severity 
and lymphoid aggregates. (A) Correlations of MC numbers with inflammatory markers, 
disease activity and histological scores. Line at p=0.05.  (B) Patients stratified according to 
mast cell numbers into low (<33rd percentile) medium (33rd-66th percentile) and high (>66th 
percentile) groups (C-D) Distribution of CD3 (C) and CD20 (D) scores in patients stratified 
according to MC numbers as in B. (E) Distribution of pathotypes in patients stratified 
according to MC numbers. (F) MC density in patients stratified according to pathotypes. 
n=99 *p=0.05, Spearman correlation in A, Chi-Square in C-E, One Way ANOVA with 
Bonferroni post-hoc test in F. 
  
Page 27 of 75
https://mc.manuscriptcentral.com/ard
Annals of the Rheumatic Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review
 O
nly
27 
 
Figure 2 Mast cells border synovial lymphoid aggregates (A) IHC staining for CD3, CD20, 
CD138 and CD68 in an US-guided biopsy of a patient with early RA classified as lymphoid 
pathotype. Semi-quantitative scores for each marker are indicated. (B) IHC staining for 
CD117 (c-kit) showing synovial MCs. High magnification, on the right, shows synovial MCs 
(arrows) close to cellular aggregates (C) Immunofluorescence staining of the RA synovia, 
showing the interactions between CD20 B cells (in green) and CD3+ T cells (in red), forming 
an ectopic lymphoid aggregate, and CD117+ MCs (in clear blue). The high magnification 
shows MCs surrounded by B and T cells at the edge of one aggregate. (D) 
Immunofluorescence of a human tonsil, showing MCs (blue) at the edge of a germinal centre 
formed by aggregates of B (green) and T cells (red).  
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Figure 3 Mast cell support survival, proliferation and differentiation of naïve B cells into 
antibody secreting cells and induce the production of ACPA autoantibodies. (A) Proportion 
of live B cells, measured by FACS staining, after 7 days of culture without (o) or with (■) 
MCs, at a ratio of 1:6, together with CPG at 1 !g/mL, n=4 (B) IgG and IgM measured by 
ELISA in the supernatants of naïve B cells harvested after 7 days of culture, n=13 for IgG 
and 7 for IgM. (C) Proportion of live cells, when naïve B cells were cultured alone or co-
cultured with MCs in contact or in transwell, n=3. (D) Proliferation measured by CFSE 
staining and FACS analysis after 7 days of culture. Representative histograms on the left and 
cumulative data with division index on the right, n=3. (E) IgG production, naïve B cells 
cultured alone or co-cultured with mast cells in contact or in transwell, n=3. (F) ACPA 
measured by CCP2 ELISA upon co-culture ACPA producing B cell clone with MCs in 
contact or transwell, n=3.  (G) IgG production upon inhibition of CD40L in the co-culture of 
MCs and B cells. n=3 (H)  Proportion of antibody-producing cells (CD27+CD38+), after 
gating on live/CD117-/CD19+.Representative histograms from 3 independent experiments. (I) 
IF of MCs (light blue) and B cells (red) after 24h of co-culture and CPG triggering. Actin re-
organisation is shown in green (phalloidin). Nuclei in blue (DAPI). Measure bar 5!m. 
Representative image of 3 independent experiments. *=p<0.05, Mann-Whitney (A and B), 
one way ANOVA with Bonferroni post-hoc (C,D, E, H). n= number of independent 
experiments  with n MC donors and n B cell donors) 
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Figure 4 Mast cells associate with ELS and disease severity in antigen induced arthritis in 
IL27ra deficient mice (A) Representative images of toluidine blue staining showing 
metachromatic mast cells (arrows) at different time-points during antigen-induced arthritis, 
with results summarized on in (B); n=>6 for each time-point. (C) Comparison of MC 
infiltration in wild type (WT) and WSX1 (IL27ra knock out) mice, and (D) representative 
images of toluidine blue staining with metachromatic MCs (red arrows) at d35 time-point. 
N= >6 /time-point/group. (E) Correlation of synovial MC numbers with arthritis index, 
synovial infiltrate and erosions at day 10. (F) Correlation of MC number with ELS area in 
IL27R KO mice at day 10 and  (G) representative image. Size bars 100 !m, unless specified. 
*p<0.05, one way ANOVA with Bonferroni in B, Mann-Whitney comparing WT and WSX1 
at each timepoint in C, Spearman correlation in E and F. 
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Supplementary Figure S1. Panel A shows an example of FACS staining of in vitro cultured 
MCs, with purity, expressed as percentage of CD117 positive cells, of 99.7% (range from 95 
to 99.7%) 
Supplementary Figure S2. Immunofluorescence for tryptase and chymase 
A Density of MCs expressing tryptase (MC_T) or tryptase and chymase (MC_TC) in 
synovia. B Density of MC_T and MC_TC in different pathotypes C Correlation between the 
density of MC_TC and Krenn synovitis score D Correlation between MC_T and Kreen 
Synovitis Score E Representative example of a patients with a lymphoid pathotype. 
Blue=DAPI (nuclei); red=tryptase; green=chymase; n= 15, representative image out of 5 
patients with lymphoid pathotype in E. Mann-Whitney in A, One-way ANOVA with 
Bonferroni post-test in B. Spearman in C-D. 
 
Page 31 of 75
https://mc.manuscriptcentral.com/ard
Annals of the Rheumatic Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review
 O
nly
!!
!
!
!"#$%&'(')**+,"-."+/'+0'1"#1'2-*.',&33',+$/.*'4".1'*5/+6"-3'"/03-22-."+/7'8"*&-*&'*&6&%".5'-/8'35291+"8'
-##%&#-.&*:''
'
(;<=(>?22' ;!!'=';!!'"#$%''
!
!
Page 32 of 75
https://mc.manuscriptcentral.com/ard
Annals of the Rheumatic Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review
 O
nly
!!
!
!
!"#$%&'(')*+,'-&..+'/0%1&%'+2304"*.'.25670"1'*##%&#*,&+''
'
89:;(8<55'=:>>';':>>'? !"''
!
!
Page 33 of 75
https://mc.manuscriptcentral.com/ard
Annals of the Rheumatic Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review
 O
nly
!!
!
!
!"#$%&'(')*+,'-&..'+$//0%,'+$%1"1*.2'/%0."3&%*,"04'*45'5"33&%&4,"*,"04'03'4*61&'7'-&..+'"4,0'*4,"8059'+&-%&,"4#'
-&..+'*45'"45$-&',:&'/%05$-,"04'03';<=;'*$,0*4,"805"&+>''
'
? !"?# $$'%(&&'"'(&&''=()''
!
!
Page 34 of 75
https://mc.manuscriptcentral.com/ard
Annals of the Rheumatic Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review
 O
nly
!!
!
!
!"#$%&'(')*+,'-&..+'*++/-"*,&'0",1'234'*56'6"+&*+&'+&7&%",8'"5'*5,"#&5'"56$-&6'*%,1%","+'"5'93:;%*'6&<"-"&5,'
="-&''
'
>?( >!?=='"#$$' '#$$'%&9'''
!
!
Page 35 of 75
https://mc.manuscriptcentral.com/ard
Annals of the Rheumatic Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review
 O
nly
  
 
 
!
!
"#$%##&&!'())!%!())!*+,-!!
 
 
Page 36 of 75
https://mc.manuscriptcentral.com/ard
Annals of the Rheumatic Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review
 O
nly
!!
!
!
!
!
"!"#$!%&&'(!))'#'!))'*+,-''
!
!
Page 37 of 75
https://mc.manuscriptcentral.com/ard
Annals of the Rheumatic Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review
 O
nly
!"##$%&%'()*+,&%(-./!,
,
#012341,5067835,049,:81;05<:49=>:2939,5?4< 208,!2<75?,,
Synovial tissue was obtained by ultrasound2guided synovial biopsy from DMARD2naïve 
patients with early (<12 months) RA (n=99), enrolled in the Pathobiology of Early Arthritis 
Cohort (PEAC) cohort (http://www.peac2mrc.mds.qmul.ac.uk) of the Centre for 
Experimental Medicine and Rheumatology of Queen Mary University (London), as 
previously described[26]. All patients fulfilled the 2010 EULAR criteria for RA[27] . Patients 
had clinically defined synovitis but duration of symptoms of less than 12 months and were all 
naïve to DMARD and steroid therapy. Upon enrollment and acquisition of demographic and 
clinical disease parameters, patients underwent ultrasound2guided synovial biopsy of a 
clinically active joint [26]. All procedures were performed following written informed 
consent and were approved by the hospital’s ethics committee (REC 05/Q0703/198). 
 
-251<8<>2"08,0408?535,<#,5?4< 208,5067835, 
3 <m formalin2fixed and paraffin2embedded (FFPE) synovial sections were deparaffinised in 
xylene (2x) and rehydrated in 100% ethanol (2x) (Sigma) and underwent standard H&E 
staining and semi2quantitative (SQ) assessment (029) of synovitis according to a previously 
validated score (Krenn)[28]. Sequentially cut sections, deparaffinized and rehydrated as 
above, underwent antigen retrieval in citrate buffer (pH 6, DAKO) at 95 °C for 30 min. After 
washing, cells were stained with the following antibodies (clone) for 1h at room temperature: 
CD20cy (L26), CD3 (F7.2.38), CD68 (KP1), CD138 (MI15), CD117, c2kit (rabbit 
polyclonal), all from DAKO. Sections were then incubated with anti2rabbit/mouse secondary 
antibody (DAKO Envision HRP) for 30 minutes at room temperature and visualised using 
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DAB (DAKO). Slides were dehydrated with 2x washes each in Xylene and 100% ethanol and 
mounted. Each slide underwent SQ scoring  (024), as previously reported[29].     
Synovial biopsies were categorized into synovial pathotypes according to the following 
criteria:   
i) Lymphoid (L) CD20≥2 and/or CD138>2 
ii) Myeloid (M) CD68SL≥2, CD20≤1 and/or CD3≥1, CD138≤2 and  
iii)  Fibroid (F) CD68SL<2 and CD3, CD20, CD138<1  
To assess the presence of MCs, we performed IHC staining for CD117 (c2kit) (DAKO) and 
used automated image analysis and counting (Olympus CellSens) to calculate the density of 
MCs. Patients were classified into high, intermediate and low MC groups (>66th, 33rd266th, 
<33rd percentile, respectively).   
 
$66:4<#8:<;35"34"3,
Sections of FFPE synovial tissue from RA patients with lymphoid pathotype (n=5) and 
tonsils from routine tonsillectomy (n=3), after deparaffinization, dehydration and antigen 
retrieval as above, underwent Immunofluorescence (IF) staining for CD3, CD20, CD117 
(DAKO) and corresponding secondary antibodies (Invitrogen)  Additional sections of FFPE 
synovial tissue from early RA patients with lymphoid (n=5), myeloid (n=5) and fibroid (n=5) 
pathotype, after deparaffinization, dehydration and antigen retrieval as above, underwent 
Immunofluorescence (IF) staining for tryptase and chymase and corresponding secondary 
antibodies (Invitrogen). Images were visualised using an Olympus microscope and CellSens 
software (Olympus). 
 
#3;27%3;08,!8<<9=93;2 39,6051,"3885,
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CD34+ hematopoietic stem cells (StemPro® CD34+ kit, ThermoFisher) were differentiated 
into MCs as previously described[30]. Briefly,  stem cells were cultured in StemPro medium 
and supplement (ThermoFischer) with 100 ng/mL of recombinant human IL26 and SCF 
(Peprotech) and, for the first week, 5 ng/mL of IL23 (Peprotech). Emi2depletion was 
performed weekly. After 628 weeks, the purity of mast cells was determined by flow 
cytometry analyses of CD117 (c2kit) and FcεRI and ranged from 90 to 99% (Supplementary 
Figure 1). 
 
'0& 3,',"388,25<8012<4,049,"<=":81:;3,(21%,&)5,
Tonsils were obtained from Barts Health NHS Trust Human Tissue Resource Centre during 
routine tonsillectomy, following written informed consent (Biobank LREC 07/Q0605/29). 
Tonsil single cell suspension were obtained by mechanical distructon through a cell strainer 
and naïve B cells (IgD+) were from isolated by immunomagnetic sorting following the the 
manufacturer’s instructions (Miltenyi). Tonsil IgD+ B cells (purity > 95%) were cultured in 
IMDM 10%FCS at a density of 1x106/mL, alone, or together with mast cells at a ratio of 1:6 
(MC:B cells), in the presence of TLR29 ligand (1 !g/mL of CpG ODN22009, Invitrogen) for 
7 days. MCs were in direct contact with B cells or separated by a Transwell© membrane. In 
parallel experiments, B cells were marked with CFSE (Biolegend) to measure proliferation. 
Where indicated, mouse anti2human CD154 (CD40L) or corresponding isotype control 
(Biolegend) were added to the co2culture at a concentration of 0.1210 !g/mL. 
 
*25:082+012<4,<#,&)=',"388,2413;0"1<4,,
Human B cells (CD19+) were immunomagnetically selected from Buffy coat of healthy 
blood donors (NHSBT, National Blood Service, UK) using CD19+ magnetic beads, 
according to the manufacturer’s instructions (Miltenyi). B cells were cultured with human 
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MCs at a ratio of 1:1. After 24 h, cells were harvested, washed in PBS and stained with anti2
CD117 APC (Miltenyi), anti2CD19 PE (R&D) for 20min at 4oC. Cells were washed, fixed in 
PFH 4% for 10 minutes at room temperatures, then incubated with CytoPainter Phalloidin2
iFluor 488 Reagent (Abcam) diluted 1:1000 in PBS/1%BSA for 30 min at RT. After washing,  
cells were transfererd on slide by cytospin and visualized using an Olympus microscope and 
CellSens Software. 
,
))#),',"388,"8<43,049,"<=":81:;3,(21%,&)5,
ACPA2producing immortalized B2cells (2 x 105) were obtained as described (Germar, K  et 
al. Manuscript submitted and[31])!and cultured on irradiated mouse L cell fibroblast stably 
expressing CD40L (5x104) in Iscove's Modified Dulbecco's Medium (IMDM) (Thermo) 
supplemented with P/S (Thermo), 8% FCS (Gibco) and IL221 (25 ng/ml). B2cells were 
passaged twice a week until used for the coculture experiment. For coculture experiments, B2
cells were cultured with mast cells at a ration of 1:6 for 7 days.  
 
,8<(,"?1<631;?,
Flow cytometry staining was performed as previously described[32]. Zombie NIR 
(Biolegend) was used to exclude dead cells and assess the proportion of live B cells, and the 
antibodies are listed in the supplementary materials. Cells were acquired on LSR Fortessa 
(BD) and the results were analysed using FlowJo software (v X.0.7, Tree Star Inc.). The 
following antibodies were used: FcεRI FITC (MAR21), CD27 APC (0323), CD20 
PerCPCy5.5 (2H7) from eBioscience; CD19 BV510 (HIB19), CD38 BV711 (HIT2), and IgD 
PE (IA622) from Biolegend, CD117 APC (A3C6E2) from Miltenyi. 
 
&305:;36341,<#,266:4<>8<!:8245,
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IgG and IgM were measured using the IgG and IgM ELISA Kits (Bethyl), according to the 
manufacturer instructions. For the measurement of ACPA, anti2CCP22IgG was measured by 
ELISA (Immunoscan2RA Mark 2; Eurodiagnostica, Arnhem, The Netherlands). 
 
)412>34,249:"39,0;1%;2125,24,(289=1?73,049,$$=-.*,/.,
AIA was induced in adult (8–12 wk) Il227ra2/2 mice and age/sex2matched WT as previously 
described[33]. FFPE 5 !m sections of synovia from animals culled at different intervals (days 
3, 10 and 35) were processed, stained and analysed as described in [29]. Sequentially2cut 
sections were deparaffinized and stained in acidic Toluidine Blue (Sigma) 0.1% solution (pH 
2.0~2.5) for 2 min, then washed, dehydrated 2x with 100% ethanol, cleared 2x with xylene 
and mounted. Slides were acquired using an Olympus microscope with CellSens Software 
(Olympus) and metachromatic MCs in synovia were counted by two blind independent 
observers (FR, DM) and expressed as the mean of two observations for each sample. 
Interobserver agreement was evaluated using the intraclass correlation coefficient (with a 
cutoff value of .0.7 to indicate acceptable agreement). 
 
!1012512"08,0408?535,
Measures of central tendency and dispersions and statistical analyses are indicated in each 
figure legend. The following statistical tests were used: Mann2Whitney for comparison 
between two groups; one2way ANOVA with Bonferroni’s post2hoc for comparison between 
multiple groups; Chi2Square for proportions; Spearman for correlations. Analyses were 
performed using IBM SPSS v23 (IBM) for clinical datasets and Graphpad Prism v5 for 
experimental datasets. P values of <0.05 were considered statistically significant.,
,
,
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Comments to the Author 
The authors have addressed most comments from the reviewers and included new data on 
mast cell subsets that have increased the value of the current mansucript. However, the 
potential causality between mast cells and ELS formation is not addressed properly. The 
authors state that the background of the mice that could be used for studying development of 
ELS (chronic model of antigen-induced arthritis) is incompatible with the genetic background 
of mast cell-deficient mice. This may be true, but there are other ways to deplete mast cells in 
vivo, for instance by administration of depleting antibodies (i.e. anti–c-kit mAb) or via 
CRISPR/Cas. 
Therefore, I would strongly urge the authors to perform these studies to enhance their data. 
 
We would like to thank the Reviewer for his additional comments. We do agree the manuscript has 
improved significantly with the addition of data on MC subsets, an analysis performed following a 
relevant suggestion from the Reviewer, for which we are extremely thankful.  
As for the potential causality between mast cells and ELS formation, we do agree this is an 
important point. To overcome the issues mentioned in our previous reply the Reviewer suggests 
trying alternative approaches. Although we appreciate this feedback, we feel that the use of anti-C-
kit antibodies would lead to inconclusive results, as it would deplete all hematopoietic progenitors 
expressing C-kit and NOT exclusively MC. In fact, c-kit-depletion has been explored as a bone 
marrow pre-transplant conditioning strategy (Blood 2004 104:4963). As for the use of CRISPR/Car 
technology, we are sure the Reviewer appreciates the complexity and time required to create new 
animal strains de novo, with delaying of publication of the human observations by a year or more.  
 
In any case, even if we were able to get a different MC-deficient strain from collaborators, the 
results of such experiments would not be necessarily transferable to the human disease (the focus of 
our manuscript). In addition, while we agree that confirmation in animal models would be 
important to show causality in that system, our manuscript does not claim we demonstrate causality 
but only that MCs are associated with ELS, as without spontaneous gene mutations in humans is 
almost impossible to demonstrate causality.  
 
Nonetheless, we provide data at different levels to indicate that MCs are not simple bystanders in 
the pathogenesis of RA, including the presence of MC in the disease tissue of a large cohort of 
patients with early rheumatoid arthritis prior to therapeutic intervention, their functional ability to 
activate / differentiate B cells leading to auto-antibody production and their association with disease 
severity. 
 
Accordingly, following the helpful Reviewer’s comments, we have modified the title omitting the 
association with “lymphoid aggregates” and inserting the association with “disease severity” (see 
also below) as follows: “Mast cells in early rheumatoid arthritis associate with disease severity and 
support B-cell autoantibody production”.  
 
We hope that Reviewer will agree that by deleting the association with lymphoid aggregates in the 
title we avoid possible misinterpretation on causality between MC and ELS formation.  
 
In their response 1.1. the authors conclude that synovial mast cells associate with disease 
severity, independently of their association with lymphoid aggregates. Therefore, the title of 
the manuscript should be changed (i.e. incorporate disease activity) and this information 
should also be included in the abstract and discussion. 
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We thank the Reviewer for this comment. We do agree that mentioning “disease severity” in the 
title (see above) provides a more balanced reflection of the clinical and immunological data 
presented in the manuscript.  Following the Reviewer’ suggestion, we have also specifically 
mentioned this new analysis in the results (page 12 “To exclude that the association of MCs with 
disease severity was exclusively driven by their association with lymphoid cells, we performed 
additional analyses excluding lymphoid patients, and found that MCs were significantly correlated 
with ESR (Spearman r=0.272 p=0.007), CRP (r=0.217 p=0.033), and DAS-28 (r=0.308 p=0.002). 
Overall, this suggests that the stratification of patients according to synovial MCs identifies patients 
with a severe clinical phenotype”). The association of MCs with disease activity has been already 
highlighted in the abstract results (“High synovial MC counts are associated with local and systemic 
inflammation, autoantibody positivity, and high disease activity”), and manuscript conclusions (“… 
their presence contributes to the definition of a MC-rich highly inflamed synovial pathotype and 
helps identifying patients with a severe clinical phenotype”).  We have now stressed the correlation 
of MCs with disease severity also in the abstract conclusions: “Synovial MCs identify early RA 
patients with a severe clinical form of synovitis characterised by the presence of ELS”. 
 
 
In their response 2, the authors state that they have included a sentence on mast cells and IL-
10 competent B cells (p.18). However, they should also include the essential information that 
the interaction between these cells is also mediated via CD40/CD40L interaction which 
consequently may also have a regulatory function. 
We have now specified this: “Interestingly, MCs were also shown to control, via CD40/CD40L 
interaction, the expansion and differentiation of IL-10-competent B cells, which is in line with their 
immunomodulatory functions”. 
 
In their response 3, the authors do not reference the Mion paper that they mentioned in their 
response 2.  
We mention the previous work by Merluzzi et al 2010, from the same group. Both papers were 
already cited in our manuscript. Furthermore, it is important to emphasise that in both papers the 
functional experiments were performed in animals, NOT humans.  
 
In addition, these authorsy overlook quite a few papers that either demonstrate human B cell 
activation by mast cells (1: Ryzhov S, Goldstein AE, Matafonov A, Zeng D, Biaggioni I, 
Feoktistov I. Adenosine-activated mast cells induce IgE synthesis by B lymphocytes: an A2B-
mediated process involving Th2 cytokines IL-4 and IL-13 with implications for asthma. J 
Immunol. 2004 Jun 15;172(12):7726-33. PubMed PMID: 15187156. 
2: Pawankar R, Okuda M, Yssel H, Okumura K, Ra C. Nasal mast cells in perennial allergic 
rhinitics exhibit increased expression of the Fc epsilonRI, CD40L, IL-4, and IL-13, and can 
induce IgE synthesis in B cells. J Clin Invest. 1997 Apr 1;99(7):1492-9. PubMed PMID: 
9119992; PubMed Central PMCID: PMC507968.) or even highlight the importance of 
CD40/CD40L in this process (1: Tournilhac O, Santos DD, Xu L, Kutok J, Tai YT, Le Gouill 
S, Catley L, Hunter  
Z, Branagan AR, Boyce JA, Munshi N, Anderson KC, Treon SP. Mast cells in Waldenstrom's 
macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling. 
Ann Oncol. 2006 Aug;17(8):1275-82. Epub 2006 Jun 20. PubMed 
PMID: 16788002. 
2: Gauchat JF, Henchoz S, Mazzei G, Aubry JP, Brunner T, Blasey H, Life P, Talabot D, 
Flores-Romo L, Thompson J, et al. Induction of human IgE synthesis in B cells by mast cells 
and basophils. Nature. 1993 Sep 23;365(6444):340-3. PubMed PMID: 7690905.). These papers 
should definitely be referenced. 
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We do agree with the Reviewer that there is additional literature on this specific topic that would 
have been worth citing. However, we had to consider the space limitations for ARD both in terms 
of total word counts (3000 words) and total citations (suggested limit of 50). Therefore, we had to 
select the most recent and relevant literature. For example, we had to leave out many significant 
manuscripts in the field of allergy, since we are already citing several recent and comprehensive 
reviews on mast cells.  
As for the specific articles mentioned, the articles by Ryzhov et al used mast cell lines (e.g. HMC-
1), which have been shown to be poorly representative of primary mast cells. 
We agree with the reviewer that it is appropriate to cite the other articles mentioned, as they deal 
with the functional role of CD40L. We have now cited these manuscripts (page 18). 
 
 
In their response 5, the authors do not respond satisfactorily to the question of the reviewer. 
Blocking the CD40/CD40L axis with blocking antibodies in the in vitro experiments with mast 
cells and ACPA+ B cell clones is quite straightforward and should not take a lot of time. 
Therefore, I persist in my request to perform these studies as in my opinion they will 
substantially increase the value of the manuscript. 
 
While we agree with the Reviewer that these experiments would be technically straightforward, 
they would be logistically challenging, as performed by external collaborators (the Leiden group), 
who currently do not have dedicated resources to carry out these time consuming experiments (MC 
differentiation takes up to 8 weeks).  
 
Importantly, we feel that these experiments would not change dramatically the impact of the paper, 
as this already shows, for the first time, that human MC can induce the differentiation of naïve B 
cells into IgG producing B cells via CD40L and the production of ACPA in a contact-dependent 
manner. Nonetheless, to be on the caution side, we have now removed the mention on the possible 
role of CD40L expressed by MCs in the induction of ACPA by B cells (page 18, line 21).   
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%
%?&.-,0:.+ Mast cells (MCs) are involved in the pathogenesis of rheumatoid arthritis (RA). 
However, their contribution remains controversial. To establish their role in RA, we analysed 
their presence in the synovium of treatment;naïve early RA patients and their association and 
functional relationship with histological features of synovitis.%
).,478+ Synovial tissue was obtained by ultrasound;guided biopsy from treatment;naïve 
patients with early RA (n=99). Immune cells (CD3/CD20/CD138/CD68) and their 
relationship with CD117+ MCs in synovial tissue were analysed by immunohistochemistry 
(IHC) and immunofluorescence (IF). The functional involvement of MCs in ectopic 
lymphoid structures (ELS) was investigated !"#$!%&', by co;culturing MCs with naïve B cells 
and anti;citrullinated protein antibodies (ACPA);producing B cell clones, and !"# $!$' in 
interleukin;27 receptor (IL27&();deficient and control mice during antigen;induced arthritis 
(AIA). 
$.+5/,+% High synovial MC counts are associated with local and systemic inflammation, 
autoantibody positivity, and high disease activity. IHC/IF showed that MCs reside at the 
outer border of lymphoid aggregates. Furthermore, human MCs promote the activation and 
differentiation of naïve B cells, and induce the production of ACPA, mainly via contact;
dependent interactions. In AIA, synovial MC numbers increase in IL27&( deficient mice, in 
association with ELS and worse disease activity) 
 71-/5+071+ Synovial MCs identify are closely associated with the presence of synovial ELS 
in early RA patients where they contribute to B;cell activation and the development of local 
inflammatory and autoimmune responses. Thus, high numbers of synovial MCs in early RA 
Page 47 of 75
https://mc.manuscriptcentral.com/ard
Annals of the Rheumatic Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review
 O
nly
3 
 
patients with identify a severe clinical form of synovitis defined characterised by the presence 
of ELS. 
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'.3%9728+! Early Rheumatoid Arthritis, Synovitis, B cells, Anti;CCP 
% %
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Mast cells (MCs) are tissue;resident cells of the innate immunity, involved in several 
physiological and pathological processes, including infections, cancer and chronic 
inflammatory diseases[1,2]. They are present in the synovial membrane (SM) and have been 
implicated in contributing to the inflammatory response in several rheumatic diseases[3], 
including rheumatoid arthritis (RA)[4]. Notably, MCs are present in healthy synovia[5], but 
their number significantly increases accompanying the cellular hyperplasia characteristic of 
RA synovitis[6–8]. Many MC mediators have direct pro;arthritogenic effects[9–12], and 
MCs can be activated by several stimuli present in the synovium/synovial fluid, such as anti;
citrullinated protein antibodies (ACPA) IgG immune complexes[13]. On the other hand, 
recent evidences suggest that MC contribution to autoimmune diseases can be complex and 
multifaceted[14]. In the context of RA, for example, human MCs have been shown to exert 
immunomodulatory functions !"#$!%&'[15]. In vivo, initial findings were contrasting[16–18], 
most likely because of the use of animal models in which MC depletion was accompanied by 
anomalies of other immune cells[19]. In recent years, thanks to the development of new 
specific models of MC;depletion[20], their contribution has been confirmed to be essential in 
collagen;induced arthritis (CIA) but redundant in serum;transfer arthritis[21]. Additionally, 
their depletion in the pre;clinical phases of CIA, rather than in the established phases, was 
shown to influence the disease outcome[22]. These evidences !"# $!$' suggest that MC 
contribution to RA may be different in various disease stages, i.e. essential during the early 
phases (assessed by CIA), but somehow dispensable during the late effector phases (serum 
transfer). However, while these models are self;resolving, in RA there is chronic 
inflammation with a perpetuation of the aberrant autoimmune response; therefore, the results 
cannot be easily translated to the clinical setting. Overall, despite the substantial amount of 
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data, the role of MCs in RA remains to be clarified [4]. As RA is well;recognized as an 
heterogeneous syndrome in terms of genetic predisposition, pathogenesis, clinical[23,24], and 
histological[25] features, it could be hypothesised that MC presence and functions in the 
synovium may be different in various disease subsets. To explore this hypothesis, we 
systematically analysed the presence of MCs in the synovia of a large cohort of disease;
modifying anti;rheumatic drugs (DMARD);naïve early RA patients. Furthermore, we 
assessed their interactions with immune cells at synovial level and analysed !"# $!%&' the 
crosstalk of MCs with B cells. Finally, we evaluated the relationship between MC synovial 
infiltration and ectopic lymphoid structures (ELS) in an experimental model of synovial 
ectopic lymphoid neogenesis. 
% %
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).,478+%
 
&*,0.1,%+*6;/.+%*18%5/,2*+7518><508.8%+317:0*/%?07;+3%%
%
Synovial tissue was obtained by ultrasound;guided synovial biopsy from DMARD;naïve 
patients with early (<12 months) RA (n=99), enrolled in the Pathobiology of Early Arthritis 
Cohort (PEAC) cohort of the Centre for Experimental Medicine and Rheumatology of Queen 
Mary University (London), as previously described[26]. All patients fulfilled the 2010 
EULAR criteria for RA[27]. All procedures were performed following written informed 
consent and were approved by the hospital’s ethics committee (REC 05/Q0703/198). 
 
+0+,7/7<0-*/%*1*/3+.+%7,%+317:0*/%+*6;/.+ 
Synovial sections underwent standard H&E staining and semi;quantitative (SQ) assessment 
of synovitis according to a previously validated score (Krenn) [28]. Sequentially cut sections 
underwent Immunohistochemical (IHC) staining and SQ assessment (0;4) for immune cells, 
as previously reported[29] and automated image analysis and counting for CD117+ve MCs. 
Patients were classified into high, intermediate and low MC groups (>66th, 33rd;66th, <33rd 
percentiles, respectively). Supplementary methods. 
 
%
%
%
%
%
%
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&.20;4.2*/%?/778>8.20:.8%) +%
CD34+ hematopoietic stem cells (StemPro® CD34+ kit, ThermoFisher) were differentiated 
into MCs as previously described[30]. Supplementary methods and Supplementary Figure 1 
for MC purity. 
 
(*-:.%=%-.//%0+7/*,071%*18%-7>-5/,52.%90,4%) +%
IgD+ B cells isolated by immunomagnetic sorting (Miltenyi) from tonsil mononuclear cells 
were cultured for 7 days alone or together with MCs, in the presence of TLR;9 ligand (CpG 
ODN;2006, Invitrogen), in contact or separated by a Transwell© membrane. In parallel 
experiments, B cells were marked with CFSE (Biolegend) to measure proliferation. Where 
indicated, mouse anti;human CD154 (CD40L) or isotype control (Biolegend) were added at a 
concentration of 0.1;10 !g/mL. Supplementary methods. 
 
.0+5*/0/*,071%7,%) >=%-.//%01,.2*-,071%%
Supplementary methods. 
%
' &'%=%-.//%-/71.%*18%-7>-5/,52.%90,4%) +%
ACPA;producing immortalized B;cells (2 x 105) were obtained as described (Germar, K et al. 
Manuscript submitted and[31])!and cultured as indicated in supplementary methods.  
 
 
0/79%-3,76.,23%
Flow cytometry staining was performed as previously described[32]. Supplemetary methods  
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).*+52.6.1,%7,%066517</7?5/01+%
IgG and IgM were measured using the IgG and IgM ELISA Kits (Bethyl), according to the 
manufacturer instructions. For the measurement of ACPA, anti;CCP2;IgG was measured by 
ELISA (Immunoscan;RA Mark 2; Eurodiagnostica). 
 
'1,0<.1%0185-.8%*2,420,0+1'"'2%01%90/8>,3;.%*18%"#34!"%'%%
AIA was induced in adult (8–12 wk) IL27&(;/; mice and age/sex;matched WT as previously 
described [33]. 5 !m sections of synovia from animals culled at different intervals (days 3, 10 
and 35) were processed and analysed as described [33]. To visualize MCs, sequentially;cut 
sections were stained with acidic Toluidine Blue (Sigma) 0.1% solution (pH 2.0~2.5). 
Supplementary methods. 
%
#,*,0+,0-*/%*1*/3+.+%
Measures of central tendency and dispersions and statistical analyses are indicated in each 
figure legend and in supplementary methods. P values of <0.05 were considered statistically 
significant.
Page 54 of 75
https://mc.manuscriptcentral.com/ard
Annals of the Rheumatic Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review
 O
nly
10 
 
$$#*#!#%
%
)*+,%-.//+%+,271</3%*++7-0*,.%90,4%8.,01.8%40+,7/7<0-*/%,.*,52.+%7,%+317:0,0+%*18%6*25.2+%
7,%80+.*+.%*-,0:0,3%01%;*,0.1,+%90,4%.*2/3%$'%
To evaluate the association of MCs with different clinical and histological phenotypes of RA 
in an unbiased setting, we studied their presence in the synovial membranes of patients with 
early RA, naïve to treatment with DMARDs. Table 1 summarises the demograhic feaures of 
the patient cohort, which are as expected for a population with early untreated RA i.e. active 
disease ; mean disease activity score (DAS);28 5.62, high inflammatory markers ; mean ESR 
38 mm/h, and approximately 70% auto;antibody positive – rheumatoid factor (RF) or ACPA. 
% %
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!*?/.%67%Summary of patient characteristics (n=99) 
'<.8%3.*2+ mean (SD), range 52 (16) 19;89 
#.9 (% Female) 70.7%  
)0+.*+.%852*,071%(Months) mean (SD), 
range 6 (3) 1;12 
' &':%  75.8%  
$0:%  73.7%  
$#$%mm/h mean (SD), range 38 (30) 2;120 
 $& mg/L mean (SD), range 17 (25) 0;162 
)'#>3;%mean (SD), range 5.62 (1.41) 1.88;8.92 
!<  mean (SD), range 11.33 (7.14) 1;28 
#<  mean (SD), range 7.33 (5.88) 1;26 
.'#%1&('2 mean (SD), range 66.25 (24.57) 0;100 
+'= mean (SD), range 1.51 (0.79) 0;4.2 
 
ACPA: anti;citrullinated protein antibodies; RF: rheumatoid factor: ESR: erythrocyte sedimentation rate; CRP: C reactive protein; DAS;28: 
disease activity score 28 joints; TJC: tender joint count; SJC: swollen joint count; VAS visual analogic scale; PGA Patient Global disease 
Activity; HAQ: health assessment questionnaire.  
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First, we assessed the correlation of MC density with markers of both local (i.e. synovial) and 
systemic inflammation and disease activity. Figure 1A demonstrates that MC counts 
significantly correlate with inflammatory markers ; erythrocyte sedimentation reate (ESR) 
and c;reactive pr tein (CRP), disease activity (DAS;28), and synovial inflammation (Krenn 
Score). Interestingly, MCs correlated with other immune cells in synovial membranes, with 
particularly high correlation indexes for B cell) and T cells scores (Spearman r 0.617 and 
0.519, respectively, p<0.001). Since MC infiltration in synovial specimens was heterogenous, 
we stratified patients according to the number of MCs into three groups (low, medium and 
high MC counts), as shown in figure 1B. Consistent with the strong correlation shown in 
figure 1A, high T and B cell scores were predominant in patients with high MC counts 
(figure 1C;D). As these data indicate that MCs correlate with synovial inflammation and the 
degree of lymphocyte infiltration, we evaluated the presence of MCs in three classified forms 
of synovitis (pathotypes): Lymphoid, Myeloid and Pauci;immune/Fibroid [25]. Interestingly, 
more than 80% of patients with high MC synovial counts displayed a lymphoid;rich 
pathotype, characterised by synovial T; and B;cell aggregates; $!*+$+&,(, as expected, the 
number of MCs was significantly higher in patients with a lymphoid pathotype (figure 1E and 
1F). These data indicate that MCs are strongly associated with lymphoid aggregates in the 
synovia of patients with early RA. Next, we investigated the heterogeneity of synovial MCs. 
Two types of MCs have been described in humans, expressing tryptase alone (MC_T) or 
tryptase and chymase (MC_TC), with the following distribution in synovium: predominance 
of MC_TC in normal synovium[5], expansion of both in RA[7], with relative incresase of 
MC_T described in early [8] and late RA [34]. By performing double immunofluorescence in 
a subgroup of patients from our early RA cohort (n=15), we found both types of MCs 
expressed in the synovia, with significantly higher levels of MC_TC  (Supplementary Figure 
S2A), and an average ratio MC_TC:MC_T of 1:3.  When patients were stratified according to 
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pathotypes, we observed a significant increase of both types of MCs in the lymphoid 
pathotype (Supplementary Figure S2B), with the ratio MC_TC:MT_C changing from 1:6 
(fibroid) to 1:2 (lymphoid). Additionally, MC_T, and not MC_TC, showed a significant 
correlation with synovial inflammation (Supplementary Figure S2C;D). Supplementary 
Figure S2E shows a representative image with a predominance  of MC_T in a patient with 
lymphoid pathotype. These data suggest an enrichment of tryptase expressing synovial MCs 
(MC_T) in the lymphoid pathotype in association with the degree of inflammation. 
Finally, we assessed the clinical phenotype of patients stratified according to MCs. As shown 
in table 2, patients with medium and high MC counts have significantly raised ESR and 
disease activity (DAS28) compared to low MC counts, and patients with high MCs have a 
significantly higher prevalence of auto;antibody positivity (ACPA and RF) compared to low 
and medium MCs. Overall, this suggests that the stratification of patients according to 
synovial MCs identifies patients with a severe clinical phenotype. To exclude that the 
association of MCs with disease severity was exclusively driven by their association with 
lymphoid cells, we performed additional analyses excluding lymphoid patients, and found 
that MCs were significantly correlated with ESR (Spearman r=0.272 p=0.007), CRP (r=0.217 
p=0.033), and DAS;28 (r=0.308 p=0.002). Overall, this suggests that the stratification of 
patients according to synovial MCs identifies patients with a severe clinical phenotype. 
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% %
!*?/.%37  Clinical phenotype of patients stratified according to MC numbers. %
  )'#!% $###  
 
'// 
11>??8%
6@@A2 
#79 
11>B32 
).8056 
11>BB2 
+0<4 
11>BC2 
'// 
11>??8%
6@@A2 
'<.%mean (SD)) 52 (16) 50 (15) 54 (17) 52 (15) 0.300 
0.6*/.%  70.7% 68.8% 71.9% 72.7% 0.704 
$#$ mean (SD) 38 (30) 27 (28) 42 (30) 45 (30) 0.033 
 $&%mean (SD) 17 (25) 10 (29) 21 (23) 18 (24) 0.174 
$0:%  73.7% 68.8% 60.6% 91.2% 0.031 
' &':%  75.8% 78.1% 60.6% 88.2% 0.009 
)'#3;%mean (SD) 5.65(1.41) 4.97 (1.54) 6.05 (1.22) 5.91 (1.24) 0.003 
00+4.2D+%.9*-,%,.+,%72%'(%.'8%*+%*;;27;20*,.% 
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)*+,%-.//+%01,.2*-,%90,4%!%*18%=%-.//+%01%,7//0-5/*2%+,25-,52.+%01%$'%+317:056%*18%,71+0/%
,0++5.%
Having established the presence of MCs in the synovial biopsies from early RA patients with  
lymphoid;rich sysnovitis, we next investigated the distribution of MCs in the synovia of 
patients with a lymphoid pathotype. A representative example of the synovial histology of 
these patients is shown in Figure 2A.  Immunohistochemical staining of sequential sections 
confirmed the presence of CD117+ synovial MCs (figure 2B). By immunofluorescence, we 
identified MCs bordering lymphoid aggregates, in close contact with B and T cells (figure 
2C). A similar distributon was observed in the highly organised secondary lymphoid organs 
(SLO) from tonsil tissue, used as controls (figure 2D).  
Thus, MCs reside on the outer boundary of B and T cell aggregates, and are a histological 
feature of both synovial ELS, and SLOs.  
%
)*+,%-.//+%.14*1-.%=%-.//+%+52:0:*/8%;27/0,.2*,071%*18%80,,.2.1,0*,071%*18%;2785-,071%7,%
-/*++>+90,-4.8%"<%*18%' &'%:0*% )C@#%
As MCs were found in the proximity of B and T cell aggregates in synovial membranes, and 
because the activation of B cells toward the production of autoantibodies locally contributes 
to the pathogenic process in RA[29], we hypothesised that human MCs could influence the 
activation of B cells. To test this hypothesis, we cultured naïve B cells isolated from tonsils 
with !"# $!%&'# differentiated human MCs, using the TLR9 ligand CpG to boost B cell 
activation[35]. MCs enhanced the survival of naïve B cells (figure 3A) with a significant 
increase in IgG secretion but only minor changes in IgM production (figure 3B). Since CpG 
-+&#,+ lacks the ability to induce a full differentiation of naïve B cells[36,37], the production 
of IgG upon co;culture of MCs with naïve B cells suggest that MCs can provide additional 
signals allowing B cell differentation and the isotype switch toward IgG (figure 3B). 
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Interestingly, cell contact was not necessary to induce the MC;mediated effect on B cell 
survival, indicating that soluble factors were sufficient (figure 3C). Additionally, MCs were 
enhancing the proliferation of CFSE;labelled naïve B cells,  and this effect was again not 
dependent on cell contact (figure 3D). On the contrary, the production of IgG was 
significantly dependent on cell contact, suggesting that membrane;bound factors were 
responsible (figure 3E). Similarly, MCs were able to ehnahce the production of RA specific 
autoantibodies (ACPA) by B cells (figure 3F), an effect again dependent on cell contact. 
Collectively, these data indicate that MCs can induce the survival, proliferation and 
differentiation of naïve B cells toward IgG;secreting B cells via indirect and direct cell;cell 
contact.  
Next, we investigated the mechanisms by which MCs promote IgG production by B cells and 
demonstrated that this is CD40L;dependent (figure 3G), confirming previous reports 
indicating that murine MCs mediate B cell activation through this cell surface costimulatory 
molecule[38,39].  
To further confirm the ability of MCs to induce the differentiation of naïve B cells toward 
antibody;producing memory B cells, we analysed B cells by flow cytometry after 7 days of 
co;culture with MCs. Figure 3H shows that co;culture of naïve B cell with MCs increased the 
number of antibody;producing memory B cells (CD27+CD38+). Interestingly, this effect 
could be inhibited by treatment with anti;CD40L in a dose;dependent manner, further 
confirming the ability of MCs to induce of B cell differentiation $!( CD40L;CD40 interaction 
(figure 3H). 
As cell contact was crucial for the MC;induced differentiation of B cells, we performed 
phalloidin staining on MCs and B cells after 24h of co;culture, which showed actin re;
organisation in the region of contact between MCs and B cells (figure 3I). This suggests an 
active cellular interaction between MCs and B cells. 
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#317:0*/% 6*+,% -.//% 01,0/,2*,071% 7--52+% .*2/3% *18% 0+% *++7-0*,.8% 90,4% $##% *18% 80+.*+.%
+.:.20,3%01%*1,0<.1>0185-.8%*2,420,0+%01%"#34!"%8.,0-0.1,%60-.%%
Having demonstrated that human MCs enhance B cell activation and differentiation !"#$!%&' 
and are associated with synovial ELS in patients with early RA, we wished to investigate !"#
$!$' the relevance of the interaction between MCs and B cells within ELS in the pathogenesis 
of arthritis. To this end, we examined MCs synovial infiltration in AIA, a model in which 
acute inflammatory arthritis is induced by intra;articular injection of methylated bovine 
serum albumin (mBSA) following systemic immunization with the same antigen. We utilised 
IL27&(;deficient mice, which develop exacerb ted synovitis comprising ELS[33]. 
Figure 4A and B show that MCs were present already in the early phases of AIA (three days 
after intra;articular injection), with their numbers further increasing at day 10 (d10) and day 
35 (d35) post;arthritis induction. Importantly, in IL27&(;deficient mice, synovial MC 
infiltration was significantly higher compared to wild;type littermates at d10 and d35 (figure 
4C;D). Moreover, at the peak of inflammation (day 10) synovial MCs showed a positive 
correlation with arthritis index, synovial infiltrate and the presence of erosions (figure 4E). 
Finally, in IL27&( deficient animals at day 10, there was a trend towards a correlation 
between MCs and the area of lymphoid aggregates (figure 4F) and MCs were found at the 
borders of lymphoid aggregates (figure 4G), reflecting the observations in RA patients with a 
lymphoid pathotype.  
Overall, these observations confirm the association of MCs with ectopic lymphoid neogenesis 
and disease severity, during arthritis induction !"#$!$'.  
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In this manuscript, we present the first systematic analysis of MCs in the synovial membrane 
(SM) of early RA patients obtained by US;guided synovial biopsy prior to therapeutic 
intervention. Our data demonstrate that synovial MCs are strongly associated with specific 
pathobiological and clinical phenotypes potentially linked to their ability to induce the 
activation/differentiation of B cells and the production of ACPA autoantibodies.  
Although MCs have long known to be part of the inflammatory infiltrate in RA, their 
presence in the SM has only been analysed in a few studies, which described increased MC 
numbers and mediators in the SM and synovial fluid of RA patients, possibly in correlation 
with disease activity[6–8]. More recently, in a study describing the immunopathologic 
characteristics of ultrasound;defined synovitis in RA patients in remission, the presence of 
synovial MCs and B cells at baseline was associated with disease reactivation at follow;
up[40]. At the same time, studies !"#$!%&' and !"#$!$' have yielded contradictory results, so 
that their exact contribution is still unclear[4].   
To obtain further insight into the relevance of MCs in RA, we analysed the SM of a large 
cohort of patients with early (<12 months) RA (n=99), unbiased by treatment and disease 
duration. 
Our data demonstrate high synovial MC counts in patients with a severe clinical phenotype at 
baseline. Furthermore, MCs correlate with synovial inflammation and, in particular, with 
ectopic lymphoid structures (ELS), which are found in approximately 40% of RA patients 
and have been associated with disease severity, T cell priming and autoantibody production, 
including the local on;going production of class;switched autoantibodies, such as 
ACPA[29,41]. Interestingly, we found a higher prevalence of tryptase;expressing MCs 
(MC_T) in the synovia of patients with ELS. Although the concept of MC heterogeneity is 
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still ill;defined[42], the prevelence of MC_T in association with the lymphoid pathotype 
would be in line with the pro;inflammatory role of this subpopulation described in 
asthma[43]. The strong association of MCs with ELS led us to hypothesise that MCs could 
modulate the local adaptive immune response. The ability of human MCs to influence T cells 
interaction has already been shown[44,45]. Murine MCs  have been shown to activate B cells 
and promote their differentiation toward effector cells[38,46]. Interestingly, murine MCs 
were also shown to control, via CD40/CD40L interaction, the expansion and differntiation of 
IL;10;competent B cells, which is in line with their immunomodulatory functions[39]. 
Nonetheless, tThe interaction of human MCs and B cells has never been poorly studied:, 
particularly in the context of allergic responses, MCs have been shown to express CD40L and 
induce IgE production by B cells[47,48], while  in the context of cancer they have been 
shown to activate lymphoplasmacytic cells via CD40L[49]. Nonetheless, the interaction 
between human MCs and B cells has notever been studied in the context of autoimmune 
diseases characterised by local B cell responses.  
Here, we show that MCs are at the border of B and T cell aggregates in the synovia of RA 
patients, similarly to the distribution observed in secondary lymphoid organs. Furthermore, 
we show that human MCs support the survival, activation, proliferation and differentiation of 
naive B cells into IgG;producing B cells, in line with recent results in mice [46]. This effect 
is dependent on cell contact and, specifically, on CD40L;CD40 interaction. Importantly, we 
demonstrate that MCs induce ACPA production by B cells, also in a contact;dependent 
manner, and thus most likely because of CD40L. Furthermore, we provide the first evidence 
of an active interaction between human MCs and B cells, as previously shown for MC;T 
cells[50] and MC;DCs[51]. ."# $!$', we used antigen;induced arthritis (AIA) to assess the 
timecourse and magnitude of synovial MC infiltration, and IL27&( deficient mice as a model 
of exacerbated synovitis accompanied by ELS formation[33], thus resembling RA patients 
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with a lymphoid pathotype. In both wild;type and IL27&( deficient animals, we observed an 
early synovial MC infiltration, before the formation of ELS, further increasing at later stages. 
Whether the early synovial infiltration of MCs means that they are essential to lymphoid 
neogenesis remains to be established. In fact, in addition to the direct modulation of 
lymphocyte  activation, MCs are also known to produce several mediators[52], including 
angiogenic and lymphangiogenic factors[53][54], that could support the organization of ELS 
[55].  Interestingly, MC numbers were significantly higher in IL27&( deficient animals, in 
association with synovial ELS and a worse disease outcome. As IL27&( deficiency has been 
shown to enhance the activation of MCs in the context of Th2 responses [56,57], it will be of 
interest to further assess the specific role of IL27;mediated MC inhibition in autoimmune 
diseases.  
In conclusion, our study points to the relevance of MCs in RA and their role as novel markers 
of synovial inflammation. In fact, their presence contributes to the definition of a MC;rich 
highly inflamed synovial pathotype and helps identifying patients with a severe clinical 
phenotype.  
 
 
 
 
 
 
 
 
 
 
Page 65 of 75
https://mc.manuscriptcentral.com/ard
Annals of the Rheumatic Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review
 O
nly
21 
 
 
 
 
 
$$0$$$( $#%
 
1  Voehringer D. Protective and pathological roles of mast cells and basophils. Nat. Rev. 
Immunol. 2013;6B:362–75. doi:10.1038/nri3427 
2  Varricchi G, Raap U, Rivellese F, +%#(/) Human mast cells and basophils;How are they 
similar how are they different? .001"'/#2+$ 2018;3;3:8–34. doi:10.1111/imr.12627 
3  Suurmond J, Van Der Velden D, Kuiper J, +%#(/) Mast cells in rheumatic disease. 31&#4#
56(&0(*'/ 2016;44;:116–24. doi:10.1016/j.ejphar.2015.03.085 
4  Rivellese F, Nerviani A, Rossi FW, +%#(/) Mast cells in rheumatoid arthritis: friends or 
foes? 71%'!001"#2+$ 2017;6E:557–63. doi:10.1016/j.autrev.2017.04.001 
5  De Paulis A, Marinò I, Ciccarelli A, +%#(/) Human synovial mast cells: I. 
Ultrastructural in situ and in vitro immunologic characte ization. 7&%6&!%!,#26+10 
1996;B?:1222–33. doi:10.1002/art.1780390723 
6  Crisp AJ, Chapman CM, Kirkham SE, +%#(/) Articular mastocytosis in rheumatoid 
arthritis. 7&%6&!%!,#26+10 1984;34:845–51. doi:10.1002/art.1780270802 
7  Gotis;Graham I, McNeil HP. Mast cell responses in rheumatoid synovium. 
Association of the MCTC subset with matrix turnover and clinical progression. 
7&%6&!%!,#26+10 1997;C@:479–89. doi:10.1002/art.1780400314 
8  Gotis;Graham I, Smith MD, Parker a., +%#(/) Synovial mast cell responses during 
clinical improvement in early rheumatoid arthritis. 7""#26+10#8!, 1998;F4:664–71. 
doi:10.1136/ard.57.11.664 
9  Hueber a. J, Asquith DL, Miller a. M, +%#(/) Cutting Edge: Mast Cells Express IL;17A 
in Rheumatoid Arthritis Synovium. 4#.001"'/ 2010;6;C:3336–40. 
doi:10.4049/jimmunol.0903566 
10  McNeil HP, Shin K, Campbell IK, +%#(/) The mouse mast cell;restricted tetramer;
forming tryptases mouse mast cell protease 6 and mouse mast cell protease 7 are 
critical mediators in inflammatory arthritis. 7&%6&!%!,#26+10 2008;F;:2338–46. 
doi:10.1002/art.23639 
!"#$%&&'()!"#$%&!'()*+,-%.!/01)2!3)4
5#1+$6!78!9%6!:%+-0+$!':%+-;.
!"#$%&&'()!:%+-0+$!':%+-;.
!"#$%&&'()!"#$%&!'()*+,-%.!/01)2!3)4
5#1+$6!78!9%6!:%+-0+$!':%+-;.
!"#$%&&'()!"#$%&!'()*+,-%.!/01)2!3)4
5#1+$6!78!9%6!:%+-0+$!':%+-;.
!"#$%&&'()!:%+-0+$!':%+-;.
!"#$%&&'()!"#$%&!'()*+,-%.!/01)2!3)4
5#1+$6!78!9%6!:%+-0+$!':%+-;.
!"#$%&&'()!"#$%&!'()*+,-%.!/01)2!3)4
5#1+$6!78!9%6!:%+-0+$!':%+-;.
!"#$%&&'()!:%+-0+$!':%+-;.
!"#$%&&'()!"#$%&!'()*+,-%.!/01)2!3)4
5#1+$6!78!9%6!:%+-0+$!':%+-;.
Page 66 of 75
https://mc.manuscriptcentral.com/ard
Annals of the Rheumatic Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review
 O
nly
22 
 
11  Sawamukai N, Yukawa S, Saito K, +%#(/) Mast cell;derived tryptase inhibits apoptosis 
of human rheumatoid synovial fibroblasts via rho;mediated signaling. 7&%6&!%!,#26+10 
2010;E3:952–9. doi:10.1002/art.27331 
12  Noordenbos T, Blijdorp I, Chen S, +%#(/) Human mast cells capture, store, and release 
bioactive, exogenous IL;17A. 4#9+1:'*#;!'/ 2016;6@@:1–10. doi:10.1189/jlb.3HI1215;
542R 
13  Suurmond J, Rivellese F, Dorjée a L, +%#(/) Toll;like receptor triggering augments 
activation of human mast cells by anti;citrullinated protein antibodies. 7""#26+10#8!, 
2015;4C:1915–23. doi:10.1136/annrheumdis;2014;205562 
14  Galli SJ, Kalesnikoff J, Grimbaldeston M a, +%#(/) Mast cells as ‘tunable’ effector and 
immunoregulatory cells: recent advances. 7""1#2+$#.001"'/ 2005;3B:749–86. 
doi:10.1146/annurev.immunol.21.120601.141025 
15  Rivellese F, Suurmond J, Habets K, +%#(/) Ability of Interleukin;33; and Immune 
Complex;Triggered Activation of Human Mast Cells to Down;Regulate Monocyte;
Mediated Immune Responses. 7&%6&!%!,#26+10(%'/ 2015;E4:2343–53. 
doi:10.1002/art.39192 
16  Lee DM, Friend DS, Gurish MF, +%#(/) Mast cells: a cellular link between 
autoantibodies and inflammatory arthritis. <*!+"*+ 2002;3?4:1689–92. 
doi:10.1126/science.1073176 
17  Pitman N, Asquith DL, Murphy G, +%#(/) Collagen;induced arthritis is not impaired in 
mast cell;deficient mice. 7""#26+10#8!, 2011;4@:1170–1. 
doi:10.1136/ard.2010.134528 
18  Zhou JS, Xing W, Friend DS, +%#(/) Mast cell deficiency in Kit(W;sh) mice does not 
impair antibody;mediated arthritis. 4#3=-#>+? 2007;3@C:2797–802. 
doi:10.1084/jem.20071391 
19  Brown M a, Hatfield JK. Mast Cells are Important Modifiers of Autoimmune Disease: 
With so Much Evidence, Why is There Still Controversy?  &'"%#.001"'/ 2012;B:147. 
doi:10.3389/fimmu.2012.00147 
20  Reber LL, Marichal T, Galli SJ. New models for analyzing mast cell functions in vivo. 
!&+"?,#.001"'/ 2012;BB:613–25. doi:10.1016/j.it.2012.09.008 
21  Schubert N, Dudeck J, Liu P, +%#(/) Mast cell promotion of T cell;driven antigen;
induced arthritis despite being dispensable for antibody;induced arthritis in which T 
cells are bypassed. 7&%6&!%!,#26+10(%'/#"#'$':+"%#&4' 2015;E4:903–13. 
doi:10.1002/art.38996 
22  Van der Velden D, Lagraauw HM, Wezel A, +%#(/) Mast cell depletion in the 
preclinical phase of collagen;induced arthritis reduces clinical outcome by lowering 
the inflammatory cytokine profile. 7&%6&!%!,#2+,#!6+& 2016;6;:138. 
doi:10.1186/s13075;016;1036;8 
Page 67 of 75
https://mc.manuscriptcentral.com/ard
Annals of the Rheumatic Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review
 O
nly
23 
 
23  Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. 9("*+% 2016;E4BE:1–16. 
doi:10.1016/S0140;6736(16)30173;8 
24  Firestein GS, McInnes IB. Immunopathogenesis of Rheumatoid Arthritis. .001"!%( 
2017;CE:183–96. doi:10.1016/j.immuni.2017.02.006 
25  Pitzalis C, Kelly S, Humby F. New learnings on the pathophysiology of RA from 
synovial biopsies. )1&&#*-!"#26+10(%'/ 2013;3F:334–44. 
doi:10.1097/BOR.0b013e32835fd8eb 
26  Kelly S, Humby F, Filer A, +%#(/) Ultrasound;guided synovial biopsy: A safe, well;
tolerated and reliable technique for obtaining high;quality synovial tissue from both 
large and small joints in early arthritis patients. 7""#26+10#8!, 2015;4C:611–7. 
doi:10.1136/annrheumdis;2013;204603 
27  Aletaha D, Neogi T, Silman AJ, +%#(/) 2010 Rheumatoid arthritis classification criteria: 
an American College of Rheumatology/European League Against Rheumatism 
collaborative initiative. 7""#26+10#8!, 2010;E?:1580–8. 
doi:10.1136/ard.2010.138461 
28  Krenn V, Morawietz L, Burmester G, +%#(/) Synovitis score: discrimination between 
chronic low;grade and high;grade synovitis. #!,%'-(%6'/'+( 2006;C?:358–64. 
doi:10.1111/j.1365;2559.2006.02508.x 
29  Humby F, Bombardieri M, Manzo A, +%#(/) Ectopic lymphoid structures support 
ongoing production of class;switched autoantibodies in rheumatoid synovium. 59'<#
>+? 2009;E:e1. doi:10.1371/journal.pmed.0060001 
30  Rådinger M, Jensen BM, Kuehn HS, +%#(/) Generation, isolation, and maintenance of 
human mast cells and mast cell lines derived from peripheral blood or cord blood. 
)1&&#5&'%'*#.001"'/ 2010; 4*;,.2%4:Unit 7.37. doi:10.1002/0471142735.im0737s90 
31  Kwakkenbos MJ, Diehl S a., Yasuda E, +%#(/) Generation of stable monoclonal 
antibody;producing B cell receptor;positive human memory B cells by genetic 
programming. &(%#>+? 2010;6E:123–8. doi:10.1038/nm.2071 
32  Rivellese F, Suurmond J, de Paulis A, +%#(/) IgE and IL;33;mediated triggering of 
human basophils inhibits TLR4;induced monocyte activation. 31&#4#.001"'/ 
2014;:3045–55. doi:10.1002/eji.201444731 
33  Jones GW, Bombardieri M, Greenhill CJ, +%#(/) Interleukin;27 inhibits ectopic 
lymphoid;like structure development in early inflammatory arthritis. 4#3=-#>+? 
2015;363:1793–802. doi:10.1084/jem.20132307 
34  Tetlow LC, Woolley DE. Distribution, activation and tryptase/chymase phenotype of 
mast cells in the rheumatoid lesion. 7""#26+10#8!, 1995;FC:549–55. 
doi:10.1136/ard.54.7.549 
35  Hua Z, Hou B. TLR signaling in B;cell development and activation. )+//#>'/#.001"'/ 
2013;6@:103–6. doi:10.1038/cmi.2012.61 
Page 68 of 75
https://mc.manuscriptcentral.com/ard
Annals of the Rheumatic Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review
 O
nly
24 
 
36  Bernasconi NL, Onai N, Lanzavecchia A. A role for toll;like receptors in acquired 
immunity: Up;regulation of TLR9 by BCR triggering in naive B cells and constitutive 
expression in memory B cells. ;/''? 2003;6@6:4500–4. doi:10.1182/blood;2002;11;
3569 
37  Jiang W, Lederman MM, Harding C V., +%#(/) TLR9 stimulation drives naïve B cells to 
proliferate and to attain enhanced antigen presenting function. 31&#4#.001"'/ 
2007;B4:2205–13. doi:10.1002/eji.200636984 
38  Merluzzi S, Frossi B, Gri G, +%#(/) Mast cells enhance proliferation of B lymphocytes 
and drive their differentiation toward IgA;secreting plasma cells. ;/''? 
2010;66F:2810–7. doi:10.1182/blood;2009;10;250126 
39  Mion F, D’Incà F, Danelli L, +%#(/) Mast Cells Control the Expansion and 
Differentiation of IL;10–Competent B Cells. 4#.001"'/ 2014;6?B:4568–79. 
doi:10.4049/jimmunol.1302593 
40  Ramírez J, Celis R, Usategui A, +%#(/) Immunopathologic characterization of 
ultrasound;defined synovitis in rheumatoid arthritis patients in clinical remission. 
7&%6&!%!,#2+,#!6+& 2016;6;:74. doi:10.1186/s13075;016;0970;9 
41  Bombardieri M, Lewis M, Pitzalis C. Ectopic lymphoid neogenesis in rheumatic 
autoimmune diseases. &(%#2+$#26+10(%'/ 2017;6B:141–54. 
doi:10.1038/nrrheum.2016.217 
42  Frossi B, Mion F, Sibilano R, +%#(/) Is it time for a new classification of mast cells? 
What do we know about mast cell heterogeneity? .001"'/#2+$ 2018;3;3:35–46. 
doi:10.1111/imr.12636 
43  Bradding P, Arthur G. Mast cells in asthma ; state of the art. )/!"#3=-#7//+&+( 
2016;CE:194–263. doi:10.1111/cea.12675 
44  Suurmond J, van Heemst J, van Heiningen J, +%#(/) Communication between human 
mast cells and CD4(+) T cells through antigen;dependent interactions. 31&#4#.001"'/ 
2013;CB:1758–68. doi:10.1002/eji.201243058 
45  Suurmond J, Habets KLL, Dorjée AL, +%#(/) Expansion of Th17 Cells by Human Mast 
Cells Is Driven by Inflammasome;Independent IL;1β. 4#.001"'/ 2016;6?4:4473–81. 
doi:10.4049/jimmunol.1502640 
46  Palm A;KE, Garcia;Faroldi G, Lundberg M, +%#(/) Activated mast cells promote 
differentiation of B cells into effector cells. <*!#2+- 2016;E:20531. 
doi:10.1038/srep20531 
47  Gauchat J;F, Henchoz S, Mazzei G, +%#(/) Induction of human IgE synthesis in B cells 
by mast cells and basophils. &(%1&+ 1993;BEF:340–3. doi:10.1038/365340a0 
48  Pawankar R, Okuda M, Yssel H, +%#(/) Nasal mast cells in perennial allergic rhinitics 
exhibit increased expression of the FcεRI, CD40L, IL;4, and IL;13, and can induce 
IgE synthesis in B cells. 4#)/!"#."$+,% 1997;??:1492–9. doi:10.1172/JCI119311 
!"#$%&&'()!"#$%&!'()*+,-%.!/01)2!3)4
5#1+$6!78!9%6!:%+-0+$!':%+-;.
!"#$%&&'()!:%+-0+$!':%+-;.
!"#$%&&'()!"#$%&!'()*+,-%.!/01)2!3)4
5#1+$6!78!9%6!:%+-0+$!':%+-;.
!"#$%&&'()!"#$%&!'()*+,-%.!/01)2!3)4
5#1+$6!78!9%6!:%+-0+$!':%+-;.
!"#$%&&'()!:%+-0+$!':%+-;.
!"#$%&&'()!"#$%&!'()*+,-%.!/01)2!3)4
5#1+$6!78!9%6!:%+-0+$!':%+-;.
!"#$%&&'()!"#$%&!'()*+,-%.!/01)2!3)4
5#1+$6!78!9%6!:%+-0+$!':%+-;.
!"#$%&&'()!:%+-0+$!':%+-;.
!"#$%&&'()!"#$%&!'()*+,-%.!/01)2!3)4
5#1+$6!78!9%6!:%+-0+$!':%+-;.
Page 69 of 75
https://mc.manuscriptcentral.com/ard
Annals of the Rheumatic Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review
 O
nly
25 
 
49  Tournilhac O, Santos DD, Xu L, +%#(/) Mast cells in Waldenstrom’s 
macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 
signaling. 7""#*"*'/ 2006;64:1275–82. doi:10.1093/annonc/mdl109 
50  Gaudenzio N, Espagnolle N, Mars LT, +%#(/) Cell;cell cooperation at the T helper 
cell/mast cell immunological synapse. ;/''? 2009;66C:4979–88. doi:10.1182/blood;
2009;02;202648 
51  Carroll;Portillo A, Cannon JL, Te Riet J, +%#(/) Mast cells and dendritic cells form 
synapses that facilitate antigen transfer for T cell activation. 4#)+//#;!'/ 2015;36@:851–
64. doi:10.1083/jcb.201412074 
52  Mukai K, Tsai M, Saito H, +%#(/) Mast cells as sources of cytokines, chemokines, and 
growth factors. .001"'/#2+$ 2018;3;3:121–50. doi:10.1111/imr.12634 
53  Detoraki A, Staiano RI, Granata F, +%#(/) Vascular endothelial growth factors 
synthesized by human lung mast cells exert angiogenic effects. 4#7//+&+(#)/!"#.001"'/ 
2009;63B:1142–9, 1149.e1–5. doi:10.1016/j.jaci.2009.01.044 
54  Varricchi G, Loffredo S, Galdiero MR, +%#(/) Innate effector cells in angiogenesis and 
lymphangiogenesis. )1&&#*-!"#.001"'/ 2018;FB:152–60. 
doi:10.1016/j.coi.2018.05.002 
55  Ruddle NH. Review series Lymphatic vessels and tertiary lymphoid organs. 
2014;63C:953–9. doi:10.1172/JCI71611.cortex 
56  Artis D, Villarino A, Silverman M, +%#(/) The IL;27 receptor (WSX;1) is an inhibitor 
of innate and adaptive elements of type 2 immunity. 4#.001"'/ 2004;64B:5626–34. 
doi:10.4049/jimmunol.173.9.5626 
57  Miyazaki Y, Inoue H, Matsumura M, +%#(/) Exacerbation of experimental allergic 
asthma by augmented Th2 responses in WSX;1;deficient mice. 4#.001"'/ 
2005;64F:2401–7. doi:10.4049/jimmunol.175.4.2401  
%
 
 
 
 
 
%
%
%
!"#$%&&'()!"#$%&!'()*+,-%.!/01)2!3)4
5#1+$6!78!9%6!:%+-0+$!':%+-;.
!"#$%&&'()!:%+-0+$!':%+-;.
!"#$%&&'()!"#$%&!'()*+,-%.!/01)2!3)4
5#1+$6!78!9%6!:%+-0+$!':%+-;.
!"#$%&&'()!"#$%&!'()*+,-%.!/01)2!3)4
5#1+$6!78!9%6!:%+-0+$!':%+-;.
!"#$%&&'()!:%+-0+$!':%+-;.
!"#$%&&'()!"#$%&!'()*+,-%.!/01)2!3)4
5#1+$6!78!9%6!:%+-0+$!':%+-;.
!"#$%&&'()!"#$%&!'()*+,-%.!/01)2!3)4
5#1+$6!78!9%6!:%+-0+$!':%+-;.
!"#$%&&'()!:%+-0+$!':%+-;.
!"#$%&&'()!"#$%&!'()*+,-%.!/01)2!3)4
5#1+$6!78!9%6!:%+-0+$!':%+-;.
!"#$%&&'()!"#$%&!'()*+,-%.!/01)2!3)4
5#1+$6!78!9%6!:%+-0+$!':%+-;.
!"#$%&&'()!:%+-0+$!':%+-;.
!"#$%&&'()!"#$%&!'()*+,-%.!/01)2!3)4
5#1+$6!78!9%6!:%+-0+$!':%+-;.
Page 70 of 75
https://mc.manuscriptcentral.com/ard
Annals of the Rheumatic Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review
 O
nly
26 
 
%
%
%
' '(%"#$)($)$(!#%
We thank Drs D. Baeten, H. Spits and H. U. Scherer for providing the immortalized ACPA;
producing B cell lines. 
0*()"((%
The research leading to these results has received funding from the People Programme 
(Marie Curie Actions) of the European Union's Seventh Framework Programme (FP7/2007;
2013) under REA grant agreement n° 608765. This work was supported in part by grants 
from the Ministero dell’Istruzione, Università e Ricerca (MIUR) and Regione Campania 
CISI;Lab Project, CRÈME Project, and TIMING Project. The Pathobiology of early arthritis 
cohort (PEAC) was funded by the MRC grant 36661. Additional funding from MRC funded 
– Maximising Therapeutic Utility for Rheumatoid Arthritis using genetic and genomic tissue 
responses to stratify medicines (MATURA) ;Grant Ref: MR/K015346/1 and ARUK funded ; 
Experimental Arthritis Treatment Centre (EATC) – Grant Ref: 20022. The animal work was 
supported by Arthritis Research UK Grants Reference 20305 & 20770.  
 76;.,01<%01,.2.+,+: None declared 
 71,20?5,72+40;: FR: study design, experiments, data acquisition, data analysis, manuscript 
preparation and revision; DM: study design, experiments, data acquisition, data analysis;  
LFJ, GJ: experiments, data acquisition, data analysis (animal data); SP, TM: experiments, 
data acquisition; AN, FH data acquisition, data analysis (clinical data); AR, SR, FK, RT, GS, 
SJ , FWR, AD, GM: interpretation of experimental results, manuscript revision; CP: study 
design, interpretation of experimental results, manuscript preparation. FR wrote the 
manuscript and all authors critically revised its final preparation and approved its submission. 
$,40-*/%*;;27:*/!%All procedures were performed following written informed consent and 
were approved by the hospital’s ethics committee (REC 05/Q0703/198). 
Page 71 of 75
https://mc.manuscriptcentral.com/ard
Annals of the Rheumatic Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review
 O
nly
27 
 
)*,*%+4*201<%+,*,.6.1,!%n.a.%0"(*$$%#$($()#%
%
00<52.%6 Association of high mast cell counts with synovial inflammation, disease severity 
and lymphoid aggregates. (A) Correlations of MC numbers with inflammatory markers, 
disease activity and histological scores. Line at p=0.05.  (B) Patients stratified according to 
mast cell numbers into low (<33rd percentile) medium (33rd;66th percentile) and high (>66th 
percentile) groups (C;D) Distribution of CD3 (C) and CD20 (D) scores in patients stratified 
according to MC numbers as in B. (E) Distribution of pathotypes in patients stratified 
according to MC numbers. (F) MC density in patients stratified according to pathotypes. 
n=99 *p=0.05, Spearman correlation in A, Chi;Square in C;E, One Way ANOVA with 
Bonferroni post;hoc test in F. 
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00<52.%3%Mast cells border synovial lymphoid aggregates%1A) IHC staining for CD3, CD20, 
CD138 and CD68 in an US;guided biopsy of a patient with early RA classified as lymphoid 
pathotype. Semi;quantitative scores for each marker are indicated. (B) IHC staining for 
CD117 (c;kit) sh wing synovial MCs. High magnification, on the right, shows synovial MCs 
(arrows) close to cellular aggregates (C) Immunofluorescence staining of the RA synovia, 
showing the interactions between CD20 B cells (in green) and CD3+ T cells (in red), forming 
an ectopic lymphoid aggregate, and CD117+ MCs (in clear blue). The high magnification 
shows MCs surrounded by B and T cells at the edge of one aggregate. (D) 
Immunofluorescence of a human tonsil, showing MCs (blue) at the edge of a germinal centre 
formed by aggregates of B (green) and T cells (red). %
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00<52.% B%Mast cell support survival, proliferation and differentiation of naïve B cells into 
antibody secreting cells and induce the production of ACPA autoantibodies7%1A) Proportion 
of live B cells, measured by FACS staining, after 7 days of culture without (o) or with (■) 
MCs, at a ratio of 1:6, together with CPG at 1 !g/mL, n=4 (B) IgG and IgM measured by 
ELISA in the supernatants of naïve B cells harvested after 7 days of culture, n=13 for IgG 
and 7 for IgM.% 1C) Proportion of live cells, when naïve B cells were cultured alone or co;
cultured with MCs in contact or in transwell, n=3. (D) Proliferation measured by CFSE 
staining and FACS analysis after 7 days of culture. Representative histograms on the left and 
cumulative data with division index on the right, n=3. (E) IgG production, naïve B cells 
cultured alone or co;cultured with mast cells in contact or in transwell, n=3. (F) ACPA 
measured by CCP2 ELISA upon co;culture ACPA producing B cell clone with MCs in 
contact or transwell, n=3.  (G) IgG production upon inhibition of CD40L in the co;culture of 
MCs and B cells. n=3 (H)  Proportion of antibody;producing cells (CD27+CD38+), after 
gating on live/CD117;/CD19+.Representative histograms from 3 independent experiments. (I) 
IF of MCs (light blue) and B cells (red) after 24h of co;culture and CPG triggering. Actin re;
organisation is shown in green (phalloidin). Nuclei in blue (DAPI). Measure bar 5!m. 
Representative image of 3 independent experiments. *=p<0.05, Mann;Whitney (A and B), 
one way ANOVA with Bonferroni post;hoc (C,D, E, H). n= number of independent 
experiments  with n MC donors and n B cell donors)%
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00<52.%C%Mast cells associate with ELS and disease severity in antigen induced arthritis in 
IL27&( deficient mice (A)% Representative images of toluidine blue staining showing 
metachromatic mast cells (arrows) at different time;points during antigen;induced arthritis, 
with results summarized on in (B); n=>6 for each time;point. (C) Comparison of MC 
infiltration in wild type (WT) and WSX1 (IL27&( knock out) mice, and (D) representative 
images of toluidine blue staining with metachromatic MCs (red arrows) at d35 time;point. 
N= >6 /time;point/group. (E) Correlation of synovial MC numbers with arthritis index, 
synovial infiltrate and erosions at day 10. (F) Correlation of MC number with ELS area in 
IL27R KO mice at day 10 and  (G) representative image. Size bars 100 !m, unless specified. 
*p<0.05, one way ANOVA with Bonferroni in B, Mann;Whitney comparing WT and WSX1 
at each timepoint in C, Spearman correlation in E and F. 
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#5;;/.6.1,*23%00<52.%#67%Panel A shows an example of FACS staining of in vitro cultured 
MCs, with purity, expressed as percentage of CD117 positive cells, of 99.7% (range from 95 
to 99.7%)%
#5;;/.6.1,*23%00<52.%#37%"66517,/572.+-.1-.%,72%,23;,*+.%*18%-436*+. 
A Density of MCs expressing tryptase (MC_T) or tryptase and chymase (MC_TC) in 
synovia. B Density of MC_T and MC_TC in different pathotypes C Correlation between the 
density of MC_TC and Krenn synovitis score D Correlation between MC_T and Kreen 
Synovitis Score E Representative example of a patients with a lymphoid pathotype. 
Blue=DAPI (nuclei); red=tryptase; green=chymase; n= 15, representative image out of 5 
patients with lymphoid pathotype in E. Mann;Whitney in A, One;way ANOVA with 
Bonferroni post;test in B. Spearman in C;D. 
 
Page 76 of 75
https://mc.manuscriptcentral.com/ard
Annals of the Rheumatic Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
